Introduction
Disease associated with porcine circovirus type 2 (PCV2) emerged in pigs in England from 1999 manifesting mainly as postweaning multisystemic wasting syndrome (PMWS). It rapidly became a significant cause of economic loss to the pig industry due to both the effects of disease on pig productivity, health and welfare and the costs relating to interventions to treatment and control. 1 Following its initial emergence and spread, the clinical and pathological presentations of porcine circovirus diseases (PCVDs) have become more diverse with enteric, hepatic, respiratory and even nervous presentations described. 2 The pathogenesis of PCVD is still not fully understood; however, the availability of commercial PCV2 vaccines globally, including in the UK, has effected a dramatic reduction on the impact of this viral infection. 3 Vaccination has proven effective in improving pig health and productivity through control of clinical disease and subclinical effects 3 4 and is widespread in commercial pig herds in the UK.
PCV2 was first characterised in 1998 and subsequent analyses, including retrospective analyses, showed that genotype PCV2a predominated in the pig population initially but there was then a global genotype shift from PCV2a to PCV2b around 2003. 5 Currently there are four recognised PCV2 genotypes: PCV2a, PCV2b, PCV2c and PCV2d. Interestingly, PCV2d was referred initially to as mutant PCV2b 6 and has recently been reclassified, along with PCV2b-1C as PCV2d and within which there appears to be two main groups, PCV2d-1 and PCV2d-2. 7 It appears that there may now be an ongoing global genotype shift from PCV2b to PCV2d. 7 Furthermore, a fifth genotype, PCV2e, has recently been proposed, based on the analysis of 10 novel sequences that were obtained from samples from 2006 to 2015 from the USA and Mexico. 8 Until very recently PCV2c had only been detected in archived samples from Denmark (1980, 1987 and 1990 ), but there is now a report that it is circulating in feral pigs in Brazil. 9 There is no evidence that PCV2c is currently circulating in the commercial pig population. All licensed PCV2 vaccines are based on the PCV2a genotype and have been shown to cross-protect against PCV2b 10 and PCV2d.
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There is no information available on the genotype of PCV2 currently circulating in the pig population in Great Britain. Data obtained during the Royal Veterinary College (RVC) PMWS project 12 The annual diagnostic rate of PCVD in Great Britain has shown a steady decline. 13 Occasional incidents are still diagnosed, which mostly arise in either unvaccinated pigs or in herds where it was known, or strongly suspected, that groups of pigs had inadvertently not been vaccinated or had some other vaccine administration issue. 14 These incidents include some with unusual presentations, such as foetopathy. 15 Occasionally, incidents have been diagnosed where no reason was identified for the occurrence of PCVD in vaccinated pigs. 13 In order to investigate PCVD incidents and obtain genotyping information for surveillance purposes, viruses associated with confirmed PCVD cases in England and Wales from 2011 to 2016 were characterised.
Materials and methods
The study investigated 65 diagnostic submissions submitted to the Animal and Plant Health Agency (APHA) Veterinary Investigation Centres from 2011 to January 2016 with a confirmed diagnosis of PCVD (in at least one pig from a submission). The APHA criteria for diagnosing PCVD in an individual pig were based on those of Sorden 16 for PMWS and of Opriessnig and others 17 for PCVD and encompass the disease presentations of PCVD more recently described by Segales. 2 They comprise three components, all of which must be present: clinical signs, histological lesions (lymphoid depletion of tissue and/or histiocytic inflammation) and the presence of PCV2 antigen (APHA use immunohistochemistry and/or the presence of typical intracytoplasmic viral inclusions as evidence) associated with the microscopic lesions.
For submissions from 2011 to 2013, one sample (one pig) per submission was investigated for this study while between 1 and 3 samples (from different pigs within a farm) were investigated for submissions from 2014 to 2016. Lymph node samples were used in preference to other tissues where available, otherwise lung or fetal heart samples were used. Samples were available either as sections cut from paraffin-embedded tissue blocks (PETBs) or fresh tissues stored frozen at -20°C from most recent cases. When sections were cut from PETB, precautions were taken including use of new microtome blades for each sample to prevent cross-contamination. Nucleic acid was extracted from PETB as described previously. 18 Digestion of the PETB sections was performed using Proteinase K (Ambion) in a digestion buffer composed of 100 mM NaCl, 0.5 per cent SDS, 10 mM Tris-HCl (pH 8) and 1 mM EDTA (pH 8). Nucleic acid was extracted from tissue using the QIAamp DNA Mini kit (Qiagen) and performed according to manufacturer's instructions. A fragment of the PCV2 genome (~760 bp), encompassing the entire coding sequence of ORF2, was amplified using primers described in Fort and others 19 and characterised by Sanger sequencing: phylogenetic analysis of ORF2 is representative of whole-genome analysis. 20 Sequences were assembled using SeqMan (DNASTAR) and subsequently aligned using MegAlign (DNASTAR). In addition, 30 unpublished PCV2b ORF2 sequences acquired during the RVC PMWS project (BBSRC project BB/FO18394/1) were included in the analysis (KY806000-KY806029). These sequences were obtained from samples collected in 2008-2009 from PMWS-affected farms in England. Reference genotypes (PCV2a-PCV2d) 21 and proposed genotype PCV2e sequences 8 were also included in the sequence analysis. Genetic distances were calculated using MEGA5 (Neighbor-Joining).
22
Results ORF2 sequences were obtained from 45 of the 65 submissions tested (Table 1) . Sequences were obtained from more than one sample (pig) in a single submission in six instances and sequences were found to be identical except for three instances for which two unique sequences were obtained (99.0-99.3 per cent identity within a submission). A total of 48 sequences were obtained from 45 submissions (Table 1) which came from 44 different farms. All but four of the 48 ORF2 sequences were 702 nucleotides in length and encoding for a protein of 234 amino acids. Nucleotide sequence identity of these 44 sequences ranged from 97.3 per cent to 100 per cent (39 unique sequences; KY806030-KY806057, KY806059-KY806069). Phylogenetic analysis showed that sequences clustered with reference PCV2b strains and that there was no obvious clustering of sequences relative to those obtained from pigs in England in [2008] [2009] (Fig 1) .
Four sequences were 705 nucleotides in length as a result of a substitution in the stop codon and that encoded for an additional amino acid (Lysine). Nucleotide sequence identity of these four sequences ranged from 99.9 per cent to 100 per cent (two unique sequences; KY806070-KY806071). These sequences clustered within genotype PCV2d (Fig 1) and specifically within group PCV2d-2 (Fig 2) . 7 Disease presentation for the majority of the 45 confirmed PCVD diagnoses comprised typical PMWS clinical signs (wasting, with or without respiratory signs, with or without diarrhoea). However, two submissions were of reproductive disease (one of which has been described in APHA's surveillance report 15 ). Both instances of reproductive disease were associated with PCV2b.
Information on farm PCV2 vaccination status was available for only 23 of the 45 submissions from which sequence data were obtained, and of these 52 per cent of farms (12 of 23) did not vaccinate. The four submissions in which PCV2d was detected were from three different farms, two of which vaccinated (at 6-8 weeks of age), while the vaccination status of the third was unknown. The pigs in which PCV2d was detected were from farms in North Yorkshire and East Anglia.
Discussion
This genotyping study of PCV2 in confirmed PCVD cases in England and Wales in 2011 to January 2016 found that the majority of sequences were genotype PCV2b; however, in the more recent samples four PCV2d sequences were identified (2013-2014). The detection of PCV2d in pigs from 3 of the 44 farms from which material was analysed is not a measure of the prevalence of PCV2d in the national herd as the material examined was only from diseased pigs and only those submitted to APHA.
It has been estimated that PCV2d originated around 20 years ago. 7 The virus was retrospectively detected in a sample from 1999 from Switzerland and has been sporadically detected since then in countries including the Netherlands (2001-2002), China (2002) and Germany (2004). 7 However, it appears that prevalence has increased in China 23 and there are now increasing reports of its detection in North America, South America, Europe and Asia. The reports suggest there is an ongoing genotypic shift from PCV2b to PCV2d. 7 24 25 The sample set in this study is not yet sufficient to state that there is an increased trend of PCV2d in England and Wales, but continued monitoring of the PCV2 genotype from disease incidents may allow analysis in the future. PCV2d was detected in a sample from one pig farm from 2013 and three samples derived from two farms from 2014. The absence of detection in samples from 2015 and to January of 2016 may simply be due to the small sample sizes (six and one submission diagnosed with PCVD, respectively). The four PCV2d ORF2 sequences from 2013 and 2014 share high nucleotide identity and indeed three of the four were identical in ORF2 sequence. The PCV2d sequences were from two regions of England representing two of the main pig-producing areas of England: the study analysed samples that had been submitted to 11 APHA Veterinary Investigation Centres.
The significance of the apparent emergence of PCV2d in pigs in England is not yet known. There is currently conflicting evidence with regard to potential differences in virulence relative to PCV2a and PCV2b. Guo and others 6 reported enhanced virulence in weaned, 30-day-old commercial piglets (more severe signs compatible with PMWS; more severe pathological lesions and higher viral loads; lower average daily weight gain) relative to challenge with PCV2a and PCV2b. Yet Opriessnig and others 26 found no significant difference in virulence although they did not rule out there being some difference.
Reports of the detection of PCV2d have been associated with apparent vaccine breakdown and consequently the cross-protectiveness of the PCV2a-based vaccines was questioned.
27 PCV2a-based vaccines have been shown to be effective against PCV2d challenge.
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To date there is no evidence that current vaccines are not effective against the circulating PCV2 genotypes in controlling disease, although they may be less effective in reducing the amount of virus. 28 In the present study, two of the three farms from which PCV2d was detected were known to vaccinate. On both of these, PCV2 vaccination was two or four weeks after weaning. Whether it was this delay of vaccination into the postweaning period or other factors which resulted in PCVD occurring in vaccinated pigs is not clear. Instances of apparent vaccine failure may be due to issues related to the storage, handling, administration or timing of vaccination rather than a true lack of vaccinal efficacy. Also assessing the virulence of PCV2 strains in the field is not possible because of the variation in environment, management, concurrent pathogens and other factors influencing the severity of PCVD in pigs.
PCR products for sequencing were not obtained from 20 of the submissions tested although PCV2 was known to be present from histopathological and immunohistochemical investigations. This is not unexpected as a relatively large fragment of the PCV2 genome is amplified for characterisation (~760 bp) which reduces the sensitivity of detection of the PCR. The quality of the DNA extracted from the PETB will also have affected the ability to obtain PCR product and which will be affected by the sample quality before fixation and embedding among other factors. 18 Although vaccination is effective in controlling PCV2-associated disease, it does not prevent virus infection establishing; therefore, PCV2 infection will continue to circulate in the pig population albeit at a lower rate. APHA will continue to monitor for any change in clinical or epidemiological presentation of PCVD and investigate cases of apparent vaccination failure in diagnostic submissions from pigs in England and Wales.
